CINP

Summary

CINP (cyclin dependent kinase 2 interacting protein, HGNC:23789) is a protein-coding gene on chromosome 14q32.31, encoding Cyclin-dependent kinase 2-interacting protein (Q9BW66). Component of the DNA replication complex, which interacts with two kinases, CDK2 and CDC7, thereby providing a functional and physical link between CDK2 and CDC7 during firing of the origins of replication. It is a common-essential gene (DepMap: required in 91.6% of cancer cell lines).

The protein encoded by this gene is reported to be a component of the DNA replication complex as well as a genome-maintenance protein. It may interact with proteins important for replication initiation and has been shown to bind chromatin at the G1 phase of the cell cycle and dissociate from chromatin with replication initiation. It may also serve to regulate checkpoint signaling as part of the DNA damage response. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 51550 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 11 total — 1 likely-pathogenic
• Phenotypes (HPO): 1
• Cancer dependency (DepMap): dependent in 91.6% of screened cell lines (common-essential)
• MANE Select transcript: NM_032630

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:23789
Approved symbol	CINP
Name	cyclin dependent kinase 2 interacting protein
Location	14q32.31
Locus type	gene with protein product
Status	Approved
Aliases	MGC849
Ensembl gene	ENSG00000100865
Ensembl biotype	protein_coding
OMIM	613362
Entrez	51550

Gene structure

Transcript identifiers

Ensembl transcripts: 9 — 3 protein_coding, 3 nonsense_mediated_decay, 2 protein_coding_CDS_not_defined, 1 retained_intron

ENST00000216756, ENST00000536961, ENST00000541568, ENST00000558523, ENST00000558764, ENST00000559504, ENST00000559514, ENST00000560326, ENST00000561468

RefSeq mRNA: 2 — MANE Select: NM_032630 NM_001320046, NM_032630

CCDS: CCDS53915, CCDS9972

Canonical transcript exons

ENST00000216756 — 5 exons

Exon	Start	End
ENSE00000660478	102355768	102355897
ENSE00002502170	102348282	102348759
ENSE00002519887	102362845	102362890
ENSE00003523399	102359419	102359587
ENSE00003639323	102349919	102350048

Expression profiles

Bgee: expression breadth ubiquitous, 196 present calls, max score 93.22.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 18.0618 / max 509.6753, expressed in 1804 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
145038	18.0618	1804

Top tissues by expression

268 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
C1 segment of cervical spinal cord	UBERON:0006469	93.22	gold quality
body of pancreas	UBERON:0001150	93.02	gold quality
monocyte	CL:0000576	91.57	gold quality
apex of heart	UBERON:0002098	91.41	gold quality
anterior cingulate cortex	UBERON:0009835	91.36	gold quality
hindlimb stylopod muscle	UBERON:0004252	91.28	gold quality
mononuclear cell	CL:0000842	91.20	gold quality
cingulate cortex	UBERON:0003027	91.19	gold quality
leukocyte	CL:0000738	91.07	gold quality
right adrenal gland	UBERON:0001233	90.86	gold quality
mucosa of transverse colon	UBERON:0004991	90.68	gold quality
right adrenal gland cortex	UBERON:0035827	90.59	gold quality
left testis	UBERON:0004533	90.56	gold quality
stromal cell of endometrium	CL:0002255	90.43	gold quality
prefrontal cortex	UBERON:0000451	90.36	gold quality
right testis	UBERON:0004534	90.17	gold quality
islet of Langerhans	UBERON:0000006	90.12	gold quality
right lobe of liver	UBERON:0001114	90.08	gold quality
left adrenal gland	UBERON:0001234	90.08	gold quality
left adrenal gland cortex	UBERON:0035825	89.95	gold quality
body of stomach	UBERON:0001161	89.91	gold quality
right frontal lobe	UBERON:0002810	89.74	gold quality
pancreas	UBERON:0001264	89.56	gold quality
right atrium auricular region	UBERON:0006631	89.26	gold quality
spinal cord	UBERON:0002240	89.10	gold quality
lower esophagus mucosa	UBERON:0035834	88.90	gold quality
granulocyte	CL:0000094	88.57	gold quality
gastrocnemius	UBERON:0001388	88.52	gold quality
amygdala	UBERON:0001876	88.38	gold quality
left coronary artery	UBERON:0001626	88.35	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	8.05
E-CURD-112	no	3.84

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

12 targeting CINP, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-185-3P	99.95	67.01	1743
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-6871-3P	99.43	68.85	741
HSA-MIR-423-5P	98.69	67.48	1522
HSA-MIR-767-3P	98.61	67.69	1192
HSA-MIR-3184-5P	98.56	67.13	1491
HSA-MIR-3151-3P	97.80	66.16	479
HSA-MIR-3116	97.07	65.78	1324
HSA-MIR-4296	96.35	63.55	1233
HSA-MIR-4265	96.18	64.68	557
HSA-MIR-4322	96.18	64.85	539

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 91.6% of screened cell lines, common-essential.

Literature-anchored findings (GeneRIF, showing 4)

• CINP is part of the Cdc7-dependent mechanism of origin firing and a functional and physical link between Cdk2 and Cdc7 complexes at the origins (PMID:16082200)
• CINP interacts with ATR-interacting protein and regulates ATR-dependent signaling, resistance to replication stress, and G2 checkpoint integrity. (PMID:19889979)
• NS5B delays cells in S phase through interaction with CINP and relocalization of the protein from the nucleus to the cytoplasm (PMID:21628470)
• Silencing CINP had the most potent inhibitory effect on cell growth in KLF5-expressing cells but did not affect parental TSU-Pr1 cells. Further analyses not only confirmed the physical interaction between KLF5 and CINP, also demonstrated that knockdown of CINP attenuated the effects of KLF5 on cell cycle progression, apoptosis and tumorigenesis. (PMID:30289973)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	cinp	ENSDARG00000073910
mus_musculus	Cinp	ENSMUSG00000021276
rattus_norvegicus	Cinp	ENSRNOG00000008035
drosophila_melanogaster	CG34174	FBGN0085203

Protein

Protein identifiers

Cyclin-dependent kinase 2-interacting protein — Q9BW66 (reviewed: Q9BW66)

All UniProt accessions (3): Q9BW66, H0YKY0, H0YN33

UniProt curated annotations — full annotation on UniProt →

Function. Component of the DNA replication complex, which interacts with two kinases, CDK2 and CDC7, thereby providing a functional and physical link between CDK2 and CDC7 during firing of the origins of replication. Regulates ATR-mediated checkpoint signaling in response to DNA damage. Part of the 55LCC heterohexameric ATPase complex which is chromatin-associated and promotes replisome proteostasis to maintain replication fork progression and genome stability. Required for replication fork progression, sister chromatid cohesion, and chromosome stability. The ATPase activity is specifically enhanced by replication fork DNA and is coupled to cysteine protease-dependent cleavage of replisome substrates in response to replication fork damage. Uses ATPase activity to process replisome substrates in S-phase, facilitating their proteolytic turnover from chromatin to ensure DNA replication and mitotic fidelity. As part of 55LCC complex, also involved in the cytoplasmic maturation steps of pre-60S ribosomal particles by promoting the release of shuttling protein RSL24D1/RLP24 from the pre-ribosomal particles.

Subunit / interactions. Homodimer. Part of the 55LCC heterohexameric ATPase complex composed at least of AIRIM, AFG2A, AFG2B and CINP. Interacts with AIRIM. Interacts with CDK2 and CDC7. Interacts with the components of the replication complex, MCM2, MCM3, MCM4, MCM5, MCM6, MCM7 and with ORC2-containing complexes. Interacts with ATRIP. Interacts with CEP152. Associates with pre-60S ribosomal particles.

Subcellular location. Nucleus.

Post-translational modifications. Phosphorylated by CDC7 but not by CDK2.

Similarity. Belongs to the CINP family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q9BW66-1	1	yes
Q9BW66-2	2
Q9BW66-3	3

RefSeq proteins (2): NP_001306975, NP_116019* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR023250	Cyclin-dep_Kinase_2_interact	Family

UniProt features (30 total): mutagenesis site 6, sequence conflict 6, helix 6, modified residue 3, splice variant 3, sequence variant 2, chain 1, coiled-coil region 1, binding site 1, strand 1

Structure

Experimental structures (PDB)

4 structures.

PDB	Method	Resolution (Å)
8CIH	X-RAY DIFFRACTION	2
9LGO	ELECTRON MICROSCOPY	3.51
9GWJ	X-RAY DIFFRACTION	3.69
8RHN	ELECTRON MICROSCOPY	4.5

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BW66-F1	88.19	0.67

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (1): 202

Post-translational modifications (3): 1, 69, 73

Mutagenesis-validated functional residues (6):

Position	Phenotype
11–14	no effect on interaction with afg2a and afg2b.
21–24	no effect on interaction with afg2a and afg2b.
162	loss of interaction with afg2a and afg2b.
178	no effect on interaction with afg2a and afg2b.
181	strongly decreases interaction with afg2a and afg2b.
184	strongly decreases interaction with afg2a and afg2b.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 92 (showing top): GOBP_RIBOSOME_BIOGENESIS, GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS, MODULE_206, GOBP_DNA_DAMAGE_RESPONSE, RFX1_02, GOBP_RIBONUCLEOPROTEIN_COMPLEX_BIOGENESIS, GOBP_RIBOSOMAL_LARGE_SUBUNIT_BIOGENESIS, chr14q32, GOBP_DNA_REPLICATION, BERENJENO_TRANSFORMED_BY_RHOA_UP, GOBP_CELL_DIVISION, GOCC_ATPASE_COMPLEX, MASSARWEH_TAMOXIFEN_RESISTANCE_UP, SANSOM_APC_MYC_TARGETS, SANSOM_APC_TARGETS_REQUIRE_MYC

GO Biological Process (6): DNA replication (GO:0006260), DNA repair (GO:0006281), ribosomal large subunit biogenesis (GO:0042273), cell division (GO:0051301), DNA damage response (GO:0006974), ribosome biogenesis (GO:0042254)

GO Molecular Function (2): preribosome binding (GO:1990275), protein binding (GO:0005515)

GO Cellular Component (1): nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
DNA metabolic process	2
ribonucleoprotein complex biogenesis	2
DNA biosynthetic process	1
DNA damage response	1
ribosome biogenesis	1
cellular process	1
cellular response to stress	1
ribonucleoprotein complex binding	1
binding	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

2212 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CINP	ATRIP	Q8WXE1	777
CINP	AIRIM	Q9NX04	592
CINP	ORC2	Q13416	587
CINP	CDC7	O00311	567
CINP	MCM5	P33992	512
CINP	NDUFB7	P17568	435
CINP	CCNA1	P78396	409
CINP	CDKN3	Q16667	400
CINP	NIT2	Q9NQR4	381
CINP	DSTN	P18282	367
CINP	GCDH	Q92947	363
CINP	AFG2B	Q9BVQ7	356
CINP	ZNF280B	Q86YH2	354
CINP	CCNE1	P24864	353
CINP	PAF1	Q8N7H5	349

IntAct

185 interactions, top by confidence:

A	B	Type	Score
AIRIM	CINP	psi-mi:“MI:0915”(physical association)	0.920
CINP	AIRIM	psi-mi:“MI:0915”(physical association)	0.920
CINP	AIRIM	psi-mi:“MI:0407”(direct interaction)	0.920
ATR	ATRIP	psi-mi:“MI:0914”(association)	0.890
CINP	AFG2A	psi-mi:“MI:0914”(association)	0.830
AFG2A	AFG2B	psi-mi:“MI:0915”(physical association)	0.800
AFG2A	AFG2B	psi-mi:“MI:0407”(direct interaction)	0.800
AFG2B	AFG2A	psi-mi:“MI:0914”(association)	0.800
AFG2A	AFG2B	psi-mi:“MI:0914”(association)	0.800
BLZF1	CINP	psi-mi:“MI:0915”(physical association)	0.780
CINP	BLZF1	psi-mi:“MI:0915”(physical association)	0.780
CLUAP1	CINP	psi-mi:“MI:0915”(physical association)	0.740
CINP	ATRIP	psi-mi:“MI:0915”(physical association)	0.730
CINP	ATRIP	psi-mi:“MI:0407”(direct interaction)	0.730
ATRIP	CINP	psi-mi:“MI:0407”(direct interaction)	0.730

BioGRID (94): CINP (Two-hybrid), CINP (Two-hybrid), CINP (Two-hybrid), C1orf109 (Two-hybrid), ATRIP (Two-hybrid), FBF1 (Two-hybrid), SYCE1 (Two-hybrid), CINP (Affinity Capture-MS), CINP (Two-hybrid), CINP (Affinity Capture-MS), CINP (Synthetic Lethality), CINP (Affinity Capture-MS), SPATA5L1 (Affinity Capture-MS), C1orf109 (Affinity Capture-MS), KIF7 (Affinity Capture-MS)

ESM2 similar proteins: A0A1B0GTZ2, A3RM20, A4UHQ4, A6H7E2, A6NGH7, A9JSR5, B0BK70, O55527, O74982, P04861, P04862, P06747, P0C137, P0C139, P0C142, P14253, P14254, P33493, P35940, P40167, P69479, P69480, P69738, Q0GBX8, Q13352, Q14BK3, Q2T9U9, Q2YDE5, Q32L17, Q3UYG1, Q4KLZ4, Q4VKV6, Q5I0J4, Q5RE16, Q66HB6, Q6AXY9, Q810N5, Q8IR45, Q8IYM0, Q8NCU1

Diamond homologs: A6H7E2, Q6GM07, Q9BW66, Q9D0V8

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
CINP	“form complex”	“SPATA5-SPATA5L1 ATPase complex”	binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

11 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	1
Likely benign	0
Benign	1

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
402142	NM_032630.3(CINP):c.637T>G (p.Ter213Gly)	Likely pathogenic

SpliceAI

897 predictions. Top by Δscore:

Variant	Effect	Δscore
14:102348755:CTCAT:C	acceptor_gain	1.0000
14:102348757:CAT:C	acceptor_gain	1.0000
14:102348760:C:CC	acceptor_gain	1.0000
14:102349911:CTACT:C	donor_loss	1.0000
14:102349912:TACTT:T	donor_loss	1.0000
14:102349913:ACTTA:A	donor_loss	1.0000
14:102349914:CTT:C	donor_loss	1.0000
14:102349915:TTA:T	donor_loss	1.0000
14:102349916:TACA:T	donor_loss	1.0000
14:102349917:A:AC	donor_gain	1.0000
14:102349917:A:C	donor_loss	1.0000
14:102349918:C:CT	donor_gain	1.0000
14:102349918:CA:C	donor_gain	1.0000
14:102349918:CAG:C	donor_gain	1.0000
14:102349918:CAGA:C	donor_gain	1.0000
14:102349918:CAGAA:C	donor_gain	1.0000
14:102349966:T:A	donor_gain	1.0000
14:102350044:TTGGT:T	acceptor_gain	1.0000
14:102350045:TGGT:T	acceptor_gain	1.0000
14:102350046:GGT:G	acceptor_gain	1.0000
14:102350047:GTCTG:G	acceptor_loss	1.0000
14:102350048:TCTGA:T	acceptor_loss	1.0000
14:102350049:C:CC	acceptor_gain	1.0000
14:102350061:C:CT	acceptor_gain	1.0000
14:102355767:CCAA:C	donor_gain	1.0000
14:102355895:TTC:T	acceptor_gain	1.0000
14:102355896:TC:T	acceptor_gain	1.0000
14:102355897:CC:C	acceptor_gain	1.0000
14:102355898:C:CC	acceptor_gain	1.0000
14:102355899:T:A	acceptor_loss	1.0000

AlphaMissense

1392 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
14:102348640:A:G	W186R	0.994
14:102348640:A:T	W186R	0.994
14:102359486:A:G	W37R	0.993
14:102359486:A:T	W37R	0.993
14:102359507:A:G	W30R	0.992
14:102359507:A:T	W30R	0.992
14:102359484:C:A	W37C	0.989
14:102359484:C:G	W37C	0.989
14:102359522:C:G	D25H	0.985
14:102349937:A:G	W140R	0.983
14:102349937:A:T	W140R	0.983
14:102349944:G:C	F137L	0.981
14:102349944:G:T	F137L	0.981
14:102349946:A:G	F137L	0.981
14:102359512:G:T	A28D	0.981
14:102359523:C:A	K24N	0.980
14:102359523:C:G	K24N	0.980
14:102348638:C:A	W186C	0.979
14:102348638:C:G	W186C	0.979
14:102355790:A:G	L95P	0.978
14:102359532:T:A	R21S	0.978
14:102359532:T:G	R21S	0.978
14:102359516:C:G	A27P	0.973
14:102359521:T:G	D25A	0.973
14:102348578:C:A	E206D	0.971
14:102348578:C:G	E206D	0.971
14:102359538:A:C	S19R	0.970
14:102359538:A:T	S19R	0.970
14:102359540:T:G	S19R	0.970
14:102359485:C:G	W37S	0.969

dbSNP variants (sampled 300 via entrez): RS1000006467 (14:102354305 C>T), RS1000050251 (14:102354939 C>G,T), RS1000122468 (14:102356165 A>G,T), RS1000491520 (14:102359128 G>A), RS1000545288 (14:102359469 A>C,G), RS1000774353 (14:102353546 A>G), RS1001619695 (14:102358874 A>G), RS1001672108 (14:102359055 T>A), RS1001954941 (14:102349772 T>A), RS1002050513 (14:102352498 T>C,G), RS1002255000 (14:102364568 G>A), RS1002342579 (14:102362971 G>A), RS1002354967 (14:102347793 G>A), RS1002515334 (14:102361889 G>T), RS1002929563 (14:102353611 CTAAT>C)

Disease associations

OMIM: gene MIM:613362 | disease phenotypes:

GenCC curated gene-disease

Mondo (2): intellectual disability (MONDO:0001071), microcephaly (MONDO:0001149)

Orphanet (1): NON RARE IN EUROPE: Unexplained intellectual disability (Orphanet:319658)

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0000252	Microcephaly

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST005951_8	Body mass index	7.000000e-09
GCST010002_161	Refractive error	1.000000e-20

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004340	body mass index

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D008607	Intellectual Disability	C10.597.606.360; C23.888.592.604.646; F01.700.687; F03.625.539
D008831	Microcephaly	C05.660.207.620; C10.500.507.400.500; C16.131.621.207.620; C16.131.666.507.400.500

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

19 total (human), top 19 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	increases abundance, increases expression, decreases expression, affects cotreatment	2
Arsenic	affects methylation, affects cotreatment, increases abundance, increases expression	2
Valproic Acid	affects expression, decreases expression	2
triphenyl phosphate	affects expression	1
pirinixic acid	affects binding, decreases expression, increases activity	1
bisphenol A	decreases methylation	1
manganese chloride	affects cotreatment, increases abundance, increases expression	1
vanadyl sulfate	decreases expression	1
bisphenol S	affects cotreatment, increases expression	1
Carbamazepine	affects expression	1
Dichlorodiphenyl Dichloroethylene	increases expression	1
Dexamethasone	affects cotreatment, increases expression	1
Diazinon	increases methylation	1
Doxorubicin	decreases expression	1
Indomethacin	affects cotreatment, increases expression	1
Manganese	increases abundance, increases expression, affects cotreatment	1
Thiram	decreases expression	1
1-Methyl-3-isobutylxanthine	affects cotreatment, increases expression	1
Copper Sulfate	decreases expression	1

Clinical trials (associated diseases)

211 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT05657860	PHASE4	COMPLETED	Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome
NCT05744479	PHASE4	RECRUITING	Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability
NCT06107829	PHASE4	WITHDRAWN	Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities
NCT06997198	PHASE4	NOT_YET_RECRUITING	Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities
NCT02270736	PHASE3	COMPLETED	Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability
NCT02304302	PHASE2	COMPLETED	Down Syndrome Memantine Follow-up Study
NCT03862950	PHASE2	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome (Met)
NCT04529226	PHASE2	UNKNOWN	Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis
NCT04821856	PHASE2	COMPLETED	Evaluation of the Effectiveness of Cannabidiol in Treating Severe Behavioural Problems in Children and Adolescents With Intellectual Disability
NCT05273320	PHASE1	COMPLETED	Clinical Trial of Nabilone for Aggression in Adults With Intellectual and Developmental Disabilities
NCT05301361	PHASE1	ENROLLING_BY_INVITATION	Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities
NCT06016764	PHASE1	COMPLETED	Use of MRI and cTBS for Catatonia in Autism
NCT06586827	PHASE1	COMPLETED	Impact of Competency-Based Training and Technical Assistance Employment Outcomes of Individuals With ID/DD
NCT07531940	PHASE1	NOT_YET_RECRUITING	Escalating Doses of Memantine in Down Syndrome (MEDS-123)
NCT03479476	PHASE2/PHASE3	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome
NCT02616796	PHASE1/PHASE2	COMPLETED	Effects of Social Gaze Training on Brain and Behavior in Fragile X Syndrome
NCT06860672	EARLY_PHASE1	RECRUITING	Clinical Trial of the Dual Vector Base Editor for the Treatment of the CHD3-R1025W Mutation
NCT00597948	Not specified	COMPLETED	Healthy Lifestyles for People With Intellectual Disabilities
NCT01087320	Not specified	RECRUITING	Genome Medical Sequencing for Gene Discovery
NCT01652963	Not specified	UNKNOWN	Picture-based Computerised Assessment and Training of Cognitive Behaviour Therapy Skills
NCT01695395	Not specified	COMPLETED	Mental Health Care Provision for Adults With Intellectual Disability and a Mental Disorder
NCT01867554	Not specified	COMPLETED	Research and Characterization of New Genes Involved in Intellectual Disability
NCT01915381	Not specified	COMPLETED	Improving Adherence Healthy Lifestyle With a Smartphone Application Based on Adults With Intellectual Disabilities
NCT01988623	Not specified	COMPLETED	Pivotal Response Treatment for Individuals With Intellectual Disabilities
NCT02099773	Not specified	COMPLETED	Support Staff-client Interactions With Augmentative and Alternative Communication
NCT02136849	Not specified	COMPLETED	Inter-regional Project of the Great Western Exploration Approach for Exome Molecular Causes Severe Intellectual Disability Isolated or Syndromic
NCT02225041	Not specified	COMPLETED	Sedation Strategy and Cognitive Outcome After Critical Illness in Early Childhood
NCT02414438	Not specified	COMPLETED	Establishing the Clinical Utility of First StepDx PLUS and NextStepDx PLUS Study
NCT02451761	Not specified	COMPLETED	Apparently Balanced Chromosomal Translocation/ Next-generation Sequencing/ Intellectual Disability
NCT02461420	Not specified	ACTIVE_NOT_RECRUITING	Mapping the Genotype, Phenotype, and Natural History of Phelan-McDermid Syndrome
NCT02461459	Not specified	ACTIVE_NOT_RECRUITING	Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC)
NCT02486081	Not specified	COMPLETED	Development and Application-Smart Football for Movement Evaluation and Training in the Special Education Population
NCT02504502	Not specified	COMPLETED	Enhancing Genomic Laboratory Reports to Enhance Communication and Empower Patients
NCT02513277	Not specified	COMPLETED	Diabetes Screening & Prevention for People With Learning (Intellectual) Disabilities:STOP Diabetes Study
NCT02561754	Not specified	COMPLETED	Weight Management for Adolescents With IDD
NCT02591446	Not specified	COMPLETED	Transcranial Magnetic Stimulation Studies in Autism Spectrum Disorders
NCT02714868	Not specified	COMPLETED	Evaluation of Project TEAM (Teens Making Environmental and Activity Modifications)
NCT02721394	Not specified	UNKNOWN	FCT With Young Children With ID in the UK: A Feasibility Project V.1
NCT02746614	Not specified	COMPLETED	Psychomotor Therapy Effects in Adaptive Behavior and Motor Proficiency in Intellectual Disability
NCT02836405	Not specified	COMPLETED	TMS for the Investigation of Brain Plasticity in Autism Spectrum Disorders